

NOW INDICATED FOR BACTERIAL VAGINOSIS...

TINDAMAX[®]

(tinidazole tablets) 250 mg
500 mg

**THE FIRST NEW
ORAL TREATMENT IN A DECADE**

**A UNIQUE COMBINATION OF
POWER**

- Proven efficacy in controlled clinical trials¹

SIMPLICITY

- Just one oral dose (two 500-mg tablets) once daily for 5 days with food

TOLERABILITY

- A generally low incidence of adverse reactions

**Substitution is NOT allowed—
there is no approved equivalent available.**

Stock up now to meet the expected demand.



Bacterial Vaginosis: Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as *Haemophilus* vaginitis, *Gardnerella* vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in non-pregnant women [see Use in Specific Populations and Clinical Studies].

Other pathogens commonly associated with vulvovaginitis such as *Trichomonas vaginalis*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Candida albicans* and *Herpes simplex virus* should be ruled out.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

WARNING: POTENTIAL RISK FOR CARCINOGENICITY

Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. **Its use should be reserved for the conditions described in INDICATIONS AND USAGE.**

AN AGGRESSIVE MARKETING CAMPAIGN WILL CREATE A STRONG DEMAND FOR TINDAMAX® (TINIDAZOLE)

**Make sure that you have adequate inventory to meet the expected requests.
Contact your wholesaler and place your order today!**

Packaging information


	TINDAMAX® 500 mg	TINDAMAX® 500 mg	TINDAMAX® 250 mg
NDC NUMBER	00178-8500-20	00178-8500-60	00178-8250-40
BOTTLE SIZE	20 Tablets	60 Tablets	40 Tablets

CONTRAINDICATIONS • Prior history of hypersensitivity to tinidazole or other nitroimidazole derivatives • First trimester of pregnancy • Nursing mothers, unless breast-feeding is interrupted during tinidazole therapy and for 3 days following the last dose

WARNINGS AND PRECAUTIONS • Seizures and neuropathy have been reported. Discontinue Tindamax if abnormal neurologic signs develop. • Vaginal candidiasis may develop with Tindamax and require treatment with an antifungal agent • Use Tindamax with caution in patients with blood dyscrasias. Tindamax may produce transient leukopenia and neutropenia.

PATIENT COUNSELING INFORMATION • Administration of Drug—Patients should be told to take Tindamax with food to minimize the incidence of epigastric discomfort and other gastrointestinal side-effects. Food does not affect the oral bioavailability of tinidazole.

• Alcohol Avoidance— Patients should be told to avoid alcoholic beverages and preparations containing ethanol or propylene glycol during Tindamax therapy and for 3 days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur. • Drug Resistance—Patients should be counseled that antibacterial drugs including Tindamax should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Tindamax is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Tindamax or other antibacterial drugs in the future.



Reference: 1. Data on file. Mission Pharmacal Company.



www.tindamax.com

© 2007 Mission Pharmacal Company, San Antonio, TX 78230-1355

All rights reserved

Printed in USA

TM:XX Revxxxx